Cannabis, CBD and Liver Health: Understanding Liver Tests in Switzerland

CBD, THC and abnormal liver tests: understand the differences, warning signs and questions to discuss with your doctor or pharmacist in Switzerland.

You use CBD oil or cannabis, and a blood test shows raised liver enzymes. Is the product responsible? Should you change how you use it? And would normal results mean everything is safe? The answers depend on the preparation, the amount you actually take, other medicines and your health. The word cannabis alone cannot tell you what a particular result means.

CBD and THC need separate consideration

A prescribed CBD solution, a THC-containing medicine and a retail hemp product are not interchangeable. Their ingredients, concentrations and intended uses differ. Being plant-derived does not establish that a product is suitable for your circumstances.

Swissmedic identifies raised liver enzymes as a relevant risk with the CBD medicine Epidyolex and specifies monitoring. This concerns a defined treatment. Its doses and monitoring requirements cannot simply be transferred to every retail CBD oil.

A randomised FDA study also found raised liver enzymes in healthy adults taking oral CBD. It tested 250–550 mg daily for four weeks. These findings do not predict an individual’s risk with different amounts, products or methods of use.

Evidence about direct liver injury from THC differs from the evidence for CBD medicines. The absence of an identical warning does not establish safety for someone with hepatitis, fatty liver disease or cirrhosis. This guide does not recommend cannabis as a treatment for liver disease.

Other cannabis risks and side effects

Metabolism, interactions and liver injury are different issues

The liver processes many substances made by the body or taken in from outside. Its involvement in cannabinoid metabolism does not, by itself, prove injury. An interaction is a separate issue: one substance may change how a medicine is cleared, affecting its intended effects or side effects.

Possible liver-cell injury needs its own assessment using symptoms, blood-test patterns, changes over time and any further investigations. A single raised result does not identify cannabis as the cause or establish a particular diagnosis. Checking whether the label says CBD or THC is only the beginning.

Understanding interactions with medicines

What the terms on your liver blood test mean

Liver tests include several different measurements. They do not all describe the same process, and they do not directly measure every aspect of liver function. Use the table below to recognise terms when discussing your results, rather than to diagnose yourself.

Your laboratory’s reference ranges, earlier results and overall circumstances matter. Normal results do not automatically make a product suitable. Equally, an abnormal result does not always mean severe or permanent injury. Ask whether repeat tests or further investigation are needed.

When to ask before starting or increasing use

An existing liver condition or previously abnormal tests are reasons to discuss CBD and THC before starting or increasing the amount. The same applies if you take several medicines or begin a new treatment. Include non-prescription medicines, herbal preparations and supplements in the discussion.

For prescribed CBD used in epilepsy, monitoring is part of treatment. The combination with valproate is particularly relevant to liver-test monitoring. Do not independently change an antiseizure medicine or another prescribed treatment; contact the team responsible promptly if problems develop.

Mention alcohol, including occasional drinking. Switching from oil to flower or choosing a different THC-to-CBD ratio does not bypass an underlying liver condition. Other methods of use may also introduce different risks.

Preparing for a conversation with your doctor or pharmacist

In Switzerland, your GP, prescriber or pharmacist can help review products and medicine combinations. Abnormal liver tests require medical assessment by a doctor. Bring the packaging or clear photographs: a few drops is not a precise description of the amount used.

Write down when you started, what you actually use and any changes before the blood test. Include recreational use as well as treatment. The information helps your care team assess the situation; it does not need to be presented as a medical use to be relevant.

Ask specific questions: could the preparation or a combination be involved? Are further investigations needed? What should happen until the next appointment? When should tests be repeated, and who will explain the results? There is no single blood-testing schedule for everyone who uses CBD.

What to bring to the review

• Product name, packaging and stated THC/CBD concentration
• Amount in mg if known, frequency and method of use
• Start date, breaks and recent changes in amount or product
• All medicines, supplements and alcohol use
• Blood-test reports, known liver conditions and new symptoms

Understanding CBD amounts and concentrations, without treating them as a personal dosing recommendation

Symptoms that should not wait for a routine appointment

New yellowing of the eyes or skin, unusually dark urine together with very pale stools, or persistent upper-abdominal symptoms need prompt medical assessment. These signs are not specific to CBD or cannabis. Do not wait until a scheduled routine blood test to report them.

For impaired consciousness, collapse or severe sudden deterioration, call 144 in Switzerland. Do not drive yourself if you are impaired. Tell the healthcare team which medicines and cannabis products you have used. Having no symptoms does not guarantee normal liver tests.

What product quality can and cannot establish

Clear ingredient information and a matching batch analysis help identify what a product contains. They cannot establish whether it suits your liver condition or other medicines. A low THC content also does not mean an item is intended for swallowing or authorised as a medicine.

A prescription, laboratory report or club membership therefore cannot replace individual assessment. The useful outcome is a clear plan for your preparation and circumstances, rather than a blanket claim that cannabis is always harmless or always harmful to the liver.

Editorial information reviewed on 27 October 2026. General guidance, not a diagnosis or an individual treatment recommendation. Medicine-specific monitoring follows current prescribing information and your treatment plan.